Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...